Compare TH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TH | NKTR |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 2017 | 1996 |
| Metric | TH | NKTR |
|---|---|---|
| Price | $18.71 | $69.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $16.50 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $320,635,000.00 | $307,711,000.00 |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $38.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $5.97 | $21.02 |
| 52 Week High | $20.85 | $109.00 |
| Indicator | TH | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 56.47 |
| Support Level | $15.95 | $64.30 |
| Resistance Level | $18.83 | $76.67 |
| Average True Range (ATR) | 0.83 | 3.45 |
| MACD | -0.11 | 1.34 |
| Stochastic Oscillator | 32.74 | 79.87 |
Target Hospitality Corp is a vertically integrated specialty rental and hospitality services company in the United States. The company provides vertically integrated specialty rental and comprehensive hospitality services, including catering food services, maintenance, housekeeping, grounds-keeping, on-site security, overall workforce lodge management, and laundry service. The company has three reportable segments: HFS - South, which provides specialty rental and hospitality services to the natural resources and development industry; WHS, which provides construction and hospitality solutions for critical mineral and data center projects; and Government, which provides specialty rental and hospitality services under government contracts.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.